New Hampshire's Medicaid Program Adds Aerocrine's FeNO Test to Their Fee Schedule
SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (OMX Nordic Exchange: AERO) today announced that New Hampshire’s Medicaid program adds FeNO reimbursement coverage, bringing the total to 32 states and the District of Columbia that now cover this test which is used in the assessment and management of asthma.